S
Sundar Jagannath
Researcher at Icahn School of Medicine at Mount Sinai
Publications - 411
Citations - 28225
Sundar Jagannath is an academic researcher from Icahn School of Medicine at Mount Sinai. The author has contributed to research in topics: Multiple myeloma & Medicine. The author has an hindex of 57, co-authored 339 publications receiving 22018 citations. Previous affiliations of Sundar Jagannath include University of Arkansas for Medical Sciences & Pfizer.
Papers
More filters
Journal ArticleDOI
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.
S. Vincent Rajkumar,Meletios A. Dimopoulos,Antonio Palumbo,Joan Bladé,Giampaolo Merlini,Maria-Victoria Mateos,Shaji Kumar,Jens Hillengass,Efstathios Kastritis,Paul G. Richardson,Ola Landgren,Bruno Paiva,Angela Dispenzieri,Brendan M. Weiss,Xavier Leleu,Sonja Zweegman,Sagar Lonial,Laura Rosiñol,Elena Zamagni,Sundar Jagannath,O. Sezer,Sigurdur Y. Kristinsson,Jo Caers,Saad Z. Usmani,Juan José Lahuerta,Hans Erik Johnsen,Meral Beksac,Michele Cavo,Hartmut Goldschmidt,Evangelos Terpos,Robert A. Kyle,Kenneth C. Anderson,Brian G.M. Durie,Jesús F. San Miguel +33 more
TL;DR: The disease definition of multiple myeloma is updated to include validated biomarkers in addition to existing requirements of attributable CRAB features (hypercalcaemia, renal failure, anaemia, and bone lesions), and specific metrics that new biomarkers should meet for inclusion in the disease definition are provided.
Journal ArticleDOI
A phase 2 study of bortezomib in relapsed, refractory myeloma.
Paul G. Richardson,Bart Barlogie,James R. Berenson,Seema Singhal,Sundar Jagannath,D. Irwin,S. Vincent Rajkumar,Gordan Srkalovic,Melissa Alsina,Raymond Alexanian,David S. Siegel,Robert Z. Orlowski,David J. Kuter,Steven Limentani,Stephanie J. Lee,Teru Hideshima,Dixie Lee Esseltine,Michael Kauffman,Julian Adams,David P. Schenkein,Kenneth C. Anderson +20 more
TL;DR: Bortezomib, a member of a new class of anticancer drugs, is active in patients with relapsed multiple myeloma that is refractory to conventional chemotherapy.
Journal ArticleDOI
An inflammatory cytokine signature predicts COVID-19 severity and survival.
Diane Marie Del Valle,Seunghee Kim-Schulze,Hsin-Hui Huang,Noam D. Beckmann,Sharon Nirenberg,Bo Wang,Yonit Lavin,Talia H. Swartz,Deepu Madduri,Aryeh Stock,Thomas U. Marron,Hui Xie,Manishkumar Patel,Kevin Tuballes,Oliver Van Oekelen,Adeeb Rahman,Patricia Kovatch,Judith A. Aberg,Eric E. Schadt,Sundar Jagannath,Madhu Mazumdar,Alexander W. Charney,Adolfo Firpo-Betancourt,Damodara Rao Mendu,Jeffrey S. Jhang,David Reich,Keith Sigel,Carlos Cordon-Cardo,Marc Feldmann,Samir Parekh,Miriam Merad,Sacha Gnjatic +31 more
TL;DR: It is proposed that serum IL-6 and TNF-α levels should be considered in the management and treatment of patients with COVID-19 to stratify prospective clinical trials, guide resource allocation and inform therapeutic options.
Journal ArticleDOI
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
Shaji Kumar,Bruno Paiva,Kenneth C. Anderson,Brian G.M. Durie,Ola Landgren,Philippe Moreau,Nikhil C. Munshi,Sagar Lonial,Joan Bladé,Maria-Victoria Mateos,Meletios A. Dimopoulos,Efstathios Kastritis,Mario Boccadoro,Mario Boccadoro,Robert Z. Orlowski,Hartmut Goldschmidt,Andrew Spencer,Jian Hou,Wee Joo Chng,Saad Z. Usmani,Elena Zamagni,Kazuyuki Shimizu,Sundar Jagannath,Hans Erik Johnsen,Evangelos Terpos,Anthony Reiman,Robert A. Kyle,Pieter Sonneveld,Paul G. Richardson,Philip L. McCarthy,Heinz Ludwig,Wenming Chen,Michele Cavo,Jean Luc Harousseau,Suzanne Lentzsch,Jens Hillengass,Antonio Palumbo,Alberto Orfao,S. Vincent Rajkumar,Jesús F. San Miguel,Hervé Avet-Loiseau +40 more
TL;DR: Several aspects of disease response assessment are clarified, along with endpoints for clinical trials, and future directions for disease response assessments are highlighted, to allow uniform reporting within and outside clinical trials.
Journal ArticleDOI
Initial genome sequencing and analysis of multiple myeloma
Michael A Chapman,Michael S. Lawrence,Jonathan J Keats,Kristian Cibulskis,Carrie Sougnez,Anna C. Schinzel,Christina L. Harview,Jean Philippe Brunet,Gregory J. Ahmann,Mazhar Adli,Mazhar Adli,Kenneth C. Anderson,Kristin G. Ardlie,Daniel Auclair,Angela Baker,P. Leif Bergsagel,Bradley E. Bernstein,Bradley E. Bernstein,Bradley E. Bernstein,Yotam Drier,Yotam Drier,Rafael Fonseca,Stacey Gabriel,Craig C. Hofmeister,Sundar Jagannath,Andrzej Jakubowiak,Amrita Krishnan,Joan Levy,Ted Liefeld,Sagar Lonial,Scott Mahan,Bunmi Mfuko,Stefano Monti,Louise M. Perkins,Robb Onofrio,Trevor J. Pugh,S. Vincent Rajkumar,Alex H. Ramos,David S. Siegel,Andrey Sivachenko,A. Keith Stewart,Suzanne Trudel,Ravi Vij,Douglas Voet,Wendy Winckler,Todd Zimmerman,John D. Carpten,Jeff Trent,William C. Hahn,William C. Hahn,Levi A. Garraway,Levi A. Garraway,Matthew Meyerson,Matthew Meyerson,Eric S. Lander,Eric S. Lander,Eric S. Lander,Gad Getz,Todd R. Golub +58 more
TL;DR: The massively parallel sequencing of 38 tumour genomes and their comparison to matched normal DNAs indicates that cancer genome sequencing of large collections of samples will yield new insights into cancer not anticipated by existing knowledge.